<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360bbb–5a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360bbb–5a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360bbb–5a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360bbb_5a"><akn:num>360bbb–5a</akn:num><akn:heading>Emerging technology program</akn:heading><akn:content><akn:p>§ 360bbb–5a. Emerging technology program(a) Program establishment(1) In generalThe Secretary shall establish a program to support the adoption of, and improve the development of, innovative approaches to drug design and manufacturing.


(2) ActionsIn carrying out the program under paragraph (1), the Secretary may—(A) facilitate and increase communication between public and private entities, consortia, and individuals with respect to innovative drug product design and manufacturing;

(B) solicit information regarding, and conduct or support research on, innovative approaches to drug product design and manufacturing;

(C) convene meetings with representatives of industry, academia, other Federal agencies, international agencies, and other interested persons, as appropriate;

(D) convene working groups to support drug product design and manufacturing research and development;

(E) support education and training for regulatory staff and scientists related to innovative approaches to drug product design and manufacturing;

(F) advance regulatory science related to the development and review of innovative approaches to drug product design and manufacturing;

(G) convene or participate in working groups to support the harmonization of international regulatory requirements related to innovative approaches to drug product design and manufacturing; and

(H) award grants or contracts to carry out or support the program under paragraph (1).


(3) Grants and contractsTo seek a grant or contract under this section, an entity shall submit an application—(A) in such form and manner as the Secretary may require; and

(B) containing such information as the Secretary may require, including a description of—(i) how the entity will conduct the activities to be supported through the grant or contract; and

(ii) how such activities will further research and development related to, or adoption of, innovative approaches to drug product design and manufacturing.




(b) GuidanceThe Secretary</akn:p></akn:content><akn:subsection eId="subsec_360bbb_5a_a"><akn:num>(a)</akn:num><akn:heading>Program establishment</akn:heading><akn:content><akn:p>(a) Program establishment</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_5a_b"><akn:num>(b)</akn:num><akn:heading>Guidance</akn:heading><akn:content><akn:p>(b) Guidance The Secretary shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_5a_c"><akn:num>(c)</akn:num><akn:heading>Report to Congress</akn:heading><akn:content><akn:p>(c) Report to Congress Not later than 4 years after December 29, 2022, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>